Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Boehringer Ingelheim Animal Health USA
WARNING LETTER
•Boehringer Ingelheim Animal Health USA•March 12, 2024

Boehringer Ingelheim Animal Health USA – FDA Warning Letter, Mar 12, 2024

Record Details

The FDA issued a Warning Letter to Boehringer Ingelheim regarding promotional communications for Senvelgo (velagliflozin oral solution), specifically the Vet Detailer on their website. The FDA found these communications make false or misleading claims about Senvelgo's safety and effectiveness, misbranding the product under FD&C Act sections 502(a), 502(n), 201(n), and 301(a), and 21 CFR 202.1(e)(5).

Senvelgo is indicated for "otherwise healthy cats with diabetes mellitus not previously treated with insulin." The product's FDA-approved labeling includes a boxed warning and contraindication against use in insulin-treated cats due to increased risk of fatal diabetic ketoacidosis (DKA) or euglycemic DKA (eDKA).

The Vet Detailer states Senvelgo demonstrated "excellent efficacy and safety in multiple pivotal clinical field trials featuring over 300 insulin-naive, previously insulin-treated, and otherwise healthy diabetic cats." This statement is false and misleading because, while some insulin-treated cats were enrolled in trials, safety and effectiveness were not demonstrated for them; 32% developed ketonuria, DKA, or eDKA and were removed. The approved labeling explicitly excludes this population.

Additionally, the Vet Detailer claims "fewer monitoring requirements" and "less-intensive monitoring" compared to

Company
Boehringer Ingelheim Animal Health USA
Inspection date
March 12, 2024
Product type
Veterinary
Office
Center for Veterinary Medicine
People
  • Linda Walter-grimm
  • Christopher Loss
View Company Profile

ID · e93d822f-ea35-4343-8a7b-bb7556a357e6

Violation Codes5
21 U.S.C. 352(a)21 U.S.C. 352(n)21 U.S.C. 321(n)21 CFR 202.1(e)(5)21 U.S.C. 331(a)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Boehringer Ingelheim Animal Health USA
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.